Filana Therapeutics, Inc. (FLNA) P/E Ratio History
Deep ValueTrading at -0.5x · 0th percentile of 5-year range · Significant discount to historical valuation · Data 2006–2014
Loading P/E history...
P/E Ratio Analysis
As of November 8, 2026, Filana Therapeutics, Inc. (FLNA) trades at a price-to-earnings ratio of -0.5x, with a stock price of $0.45 and trailing twelve-month earnings per share of $-0.87.
The current P/E is 115% below its 5-year average of 3.4x. Over the past five years, FLNA's P/E has ranged from a low of 1.0x to a high of 9.7x, placing the current valuation at the 0th percentile of its historical range.
Relative to the broader market, FLNA trades at a notable discount to the S&P 500 median P/E of 21.8x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our FLNA DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
FLNA Cross-Benchmark Valuation
How does the current P/E compare to sector peers and the broader market?
FLNA P/E vs Peers
Closest public peers sorted by market cap
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $4B | 10.3 | - | +68% | |
| $45M | 4.0Lowest | - | +14% | |
| $37B | 105.5 | - | -21% | |
| $1.3T | 43.9 | 1.52 | +96% | |
| $21B | 7.9 | - | +207%Best | |
| $45B | 32.6 | 0.80Best | +5% |
Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.
FLNA Historical P/E Data (2006–2014)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Period End | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2014 Q3 | - | $3.91 | $3.45 | 1.1x | -67% |
| FY2014 Q2 | Jun 30 2014 | $5.75 | $3.88 | 1.5x | -57% |
| FY2014 Q1 | Mar 31 2014 | $5.50 | $4.33 | 1.3x | -63% |
| FY2013 Q4 | - | $4.86 | $4.81 | 1.0x | -71% |
| FY2009 Q2 | - | $5.37 | $1.91 | 2.8x | -18% |
| FY2009 Q1 | - | $4.20 | $1.75 | 2.4x | -30% |
| FY2008 Q4 | Dec 31 2008 | $5.92 | $2.47 | 2.4x | -30% |
| FY2008 Q3 | - | $9.77 | $3.32 | 2.9x | -14% |
| FY2008 Q2 | Jun 30 2008 | $7.90 | $1.36 | 5.8x | +69% |
| FY2008 Q1 | Mar 31 2008 | $8.45 | $2.02 | 4.2x | +22% |
| FY2007 Q4 | Dec 31 2007 | $10.60 | $3.56 | 3.0x | -13% |
| FY2007 Q3 | Sep 30 2007 | $9.35 | $2.04 | 4.6x | +33% |
| FY2007 Q2 | Jun 30 2007 | $8.71 | $3.02 | 2.9x | -16% |
| FY2007 Q1 | Mar 31 2007 | $7.84 | $2.74 | 2.9x | -17% |
| FY2006 Q4 | Dec 31 2006 | $8.90 | $0.92 | 9.7x | +182% |
| FY2006 Q3 | Sep 30 2006 | $8.62 | $1.32 | 6.5x | +90% |
Average P/E for displayed period: 3.4x
FLNA Chart Terminal
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
Live Breakouts Feed
High-probability breakout stocks crossing their pivot across 5 pattern engines.
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
20+ years return with dividends reinvested.
Peer Comparison
Compare growth, multiples, and margins vs sector.
FLNA — Frequently Asked Questions
Quick answers to the most common questions about buying FLNA stock.
What is FLNA's P/E ratio?
Filana Therapeutics, Inc. (FLNA) trailing twelve-month P/E ratio is -0.5x, based on TTM diluted EPS of $-0.87. The 5-year average P/E is 3.4x and the historical range spans 1.0x to 9.7x.
Is FLNA stock overvalued or undervalued?
FLNA trades at -0.5x P/E, below its 5-year average of 3.4x. At the 0th percentile of its historical range (1.0x–9.7x), the stock is priced at a discount to its own history.
Is FLNA stock expensive?
No, FLNA is not expensive on a historical basis. The current P/E of -0.5x is below the 5-year average of 3.4x and sits at the 0th percentile of its valuation range.
What is FLNA's historical P/E range?
Over the past 5 years, FLNA's P/E ratio has ranged from 1.0x to 9.7x, with a median of 2.9x and an average of 3.4x. The current P/E of -0.5x places the stock at the 0th percentile of this range. Full historical data spans 2006–2014.
How does FLNA's P/E compare to the S&P 500?
FLNA trades at -0.5x P/E versus the S&P 500 median of 21.8x. The 102% discount to the market suggests lower growth expectations or perceived higher risk.
How does FLNA's valuation compare to sector peers?
Filana Therapeutics, Inc. P/E of -0.5x can be benchmarked against sector peers in the comparison table on this page.
What is FLNA's PEG ratio?
FLNA PEG ratio is N/A, based on a P/E of -0.5x and EPS growth of -28.8%. PEG normalises P/E by growth and helps compare stocks with different earnings trajectories.
What is FLNA's earnings yield?
FLNA earnings yield is N/A, the inverse of its -0.5x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.